SARS-CoV-2 Antibody Biosensor
The Biosensor Platform uses Organic Thin Film Transistor (OTFT) technology, which can be printed at scale, at a low cost. By substituting the detection element (region A) depending on the analyte to be detected, the Biosensor can be modified to monitor a wide range of saliva-based diagnostic analytes.
The Platform is in development to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Wyss Institute for Biologically Inspired Engineering at Harvard University is integrating our world-first Biosensor Platform technology with a specialised nanomaterial coating.
This gel-like coating allows the detection of IgM and/or igG antibodies. which indicates a person’s current or previous exposure to the SARS-CoV-2 virus, and, thus, a potential infection with COVID-19
Further development could result in a chewing-gum sized diagnostic ‘strip’ to be used as a diagnostic tool for COVID-19 testing at point of care, which:
- Is non-invasive
- Produces real-time results
- Can show quantified measures of immunity and/or exposure (rather than just a positive or negative result)
- Has the ability to be printed at scale, at a low cost
The pilot diagnostic test is Saliva Glucose. Diagnostic test portfolio includes Clinical Chemistry Tests (ie. Cholesterol).
This tumor marker test portfolio along with other tests was designed to help doctors diagnose cancer and plan treatment. Tumor markers can be used in guiding treatment decisions, monitoring treatment, predicting the chance of recovery, and predict or monitor for tumor recurrence.
The pilot diagnostic test will be allergens (peanut kernel) and the portfolio will consist of various communicable disease tests including Hepatitis A, B & C, HIV and TORCH.
The first test to be developed from a hormone category is Luteinizing Hormone (LH).
We are also exploring the application of the platform in Nucleic Acid analysis and its applications in personalized medicine.